Sun Pharmaceutical Industries Limited has successfully concluded its postal ballot process, resulting in the appointment of Ms. Satyavati Berera as an Independent Director of the company. The resolution was duly approved by shareholders with the requisite majority, marking the completion of a corporate governance exercise initiated through a formal Notice dated 07 April 2026.

Appointment Details

The following table summarises the key details of Ms. Satyavati Berera's appointment as Independent Director:

Postal Ballot Process

The postal ballot process was initiated pursuant to a Notice dated 07 April 2026, with the remote e-voting period commencing on 09 April 2026. The process was completed on 08 May 2026, upon which the resolution for Ms. Berera's appointment was confirmed as having received the requisite shareholder approval.

The details of the voting results have been submitted to the stock exchanges. The Scrutinizer's Report has been made available on the company's official website at www.sunpharma.com . The communication was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983), on behalf of Sun Pharmaceutical Industries Limited.

Sun Pharmaceutical has secured interim legal relief in a trademark dispute against United Biotech, with a court ordering United Biotech to stop using the brand name 'Otide'. The court found the name sufficiently similar to Sun Pharma's existing trademark 'Octride' to warrant temporary protection, recognising the potential reputational harm that could arise from continued use of the contested mark.

Court Grants Temporary Injunction

The court's interim order restrains United Biotech from using 'Otide' as a brand name, citing its phonetic and structural resemblance to Sun Pharma's 'Octride' trademark. The ruling reflects the court's preliminary assessment that the similarity between the two names could cause confusion in the market and potentially damage the reputation associated with Sun Pharma's established brand.

Key Details of the Dispute

The following table summarises the key parameters of the trademark dispute:

Implications of the Order

The temporary injunction prevents United Biotech from using the 'Otide' brand name until the matter is further adjudicated. The court's decision underscores the importance of trademark distinctiveness in the pharmaceutical sector, where brand names play a critical role in product identification and patient safety. Sun Pharma's successful bid for interim relief represents a significant step in protecting its intellectual property rights associated with the 'Octride' trademark.